TG Therapeutics, Inc. (NASDAQ: TGTX) is a biopharmaceutical company focused on the acquisition, development, and commercialization of pharmaceutical products that target B-cell malignancies and autoimmune diseases. The company is built around the innovation and development of novel drugs that have the potential to transform how these diseases are treated. The goal at TG Therapeutics is to enrich the quality of life and improve the survival of patients suffering from these diseases.
Based in New York City and incorporated in 1993, TG Therapeutics uses peptides, bispecific antibodies, and small molecules to stimulate and redirect the patient’s immune cells against cancer and autoimmune diseases. The company's core products are TG-1101 (ublituximab), a novel, glycoengineered monoclonal antibody, and TGR-1202, an orally available PI3K delta inhibitor. Both products are in early stage clinical development for patients with hematologic malignancies.
The company's developmental product pipeline includes innovative immunotherapies designed to treat patients with lymphoma, leukemia, and multiple sclerosis. TG Therapeutics aims to deliver safe and effective treatments to patients who present with underserved medical needs. The company's commitment to advancing novel therapeutics also extends to various partnerships aimed at expanding its portfolio and accelerating the development of its pipeline products.
TG Therapeutics operates under a "patient first" principle, striving to bring novel, convenient, and potentially life-saving therapies to patients who need them the most. By targeting the therapeutic gaps with innovative solutions, it has positioned itself as a dynamic player in the competitive biopharmaceutical industry.
The company's strategic business objectives include leveraging advanced technologies and establishing strategic collaborations for additional drug discovery and development. Over the years, it has consistently demonstrated its commitment to research and development to fulfil its vision of improving the landscape of cancer and autoimmune disease therapeutics.
TG Therapeutics' commitment to improving patient outcomes is a driving force behind their culture of innovation. The development approach they use is designed to expedite regulatory approval timelines and increase patient access to their developments. It is this ambition, coupled with commitment and passion, that drives TG Therapeutics to push boundaries and redefine standards in the biopharmaceutical industry. TG Therapeutics, Inc. (TGTX) is more than just a biopharmaceutical company; it's a community of professionals pursuing the shared goal of making a pronounced difference in the lives of patients.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
TG Therapeutics (TGTX) is anticipated to report a significant year-over-year increase in earnings and higher revenues for the quarter ended June 2026. The company is expected to post earnings of $0.41 per share, a 141.2% increase, on revenues of $230.77 million, up 63.5%. With a positive Earnings ESP of +7.98% and a Zacks Rank #3, TG Therapeutics is likely to beat the consensus EPS estimate.
TG Therapeutics (TGTX) stock has formed a cup-style base after an early August sell-off and is now testing a key moving average. While the company has shown strong recent returns, analysts have a consensus price target of $51.71, suggesting the stock is currently slightly overvalued at its last close of $56.01, or fairly priced at its current price of $53.22. However, when viewed through a P/E lens, the stock's 18x earnings is slightly above the US Biotechs average but below an estimated fair ratio of 25.7x, indicating mixed signals for investors.
TG Therapeutics (TGTX) has seen significant returns over the past three years, yet its stock appears undervalued based on current valuation checks. The company trades at a lower P/E ratio compared to its industry and peers, and its tailored fair P/E also suggests it's priced under its benchmark. The key to future valuation lies in its ability to convert its pipeline into sustainable earnings, with differing community views on its flagship product BRIUMVI.